Lv1
30 积分 2025-01-06 加入
Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers
2个月前
已完结
Comparison of immunochemotherapy followed by surgery or chemoradiotherapy in locally advanced esophageal squamous cell cancer
2个月前
已完结
Efficacy and safety of SHR-1701 combined with chemoradiotherapy as neoadjuvant treatment for locally advanced rectal cancer
2个月前
已完结
Efficacy and safety of luveltamab tazevibulin in patients with recurrent platinum-resistant ovarian cancer: Results from the dose-optimization stage of the REFRαME-O1 (GOG-3086, ENGOT-79ov, and APGOT-OV9) phase II/III study
3个月前
已完结
Tislelizumab and hypofractionated radiotherapy plus nab-paclitaxel/gemcitabine as conversion therapy for BRPC/LAPC: A Phase II trial with dynamic biomarker monitoring
3个月前
已完结
Adjuvant chemoradiation combined with immunotherapy for patients with high-risk resectable extrahepatic cholangiocarcinoma and gallbladder cancer: A phase II, multicenter, randomized controlled trial (ACCORD trial)
4个月前
已关闭
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer
4个月前
已完结
Adjuvant camrelizumab combined with capecitabine in patients with intrahepatic cholangiocarcinoma after surgical resection in China (ACC): a single-arm, single-centre, open-label, phase 2 trial
4个月前
已完结
Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma
4个月前
已完结
Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study
4个月前
已完结
皖公网安备34019202002308
